

May 03, 2017

The National Stock Exchange of India Ltd  
Exchange Plaza, Bandra Kurla Complex  
Mumbai 400051

Bombay Stock Exchange Limited  
1<sup>st</sup> floor, Rotunda Building, Dalal Street  
Fort, Mumbai 400001

Dear Sir/Madam,

**Sub: Outcome of the Board meeting held today.**

With reference to the above captioned subject, we are enclosing herewith a copy of un-audited Financial Results along with the Limited Review Report for the quarter ended March 31, 2017 as approved by the Board of Directors of the Company at its meeting held on May 03, 2017.

The Un-audited Financial Results will be published in the newspapers within the stipulated time as per the SEBI Listing Regulations.

Kindly take the same on record.

Thanking you,

**Yours faithfully,  
For Merck Limited**



**Vikas R Gupta**  
**General Counsel & Company Secretary**  
Encl : As above



**Merck Limited**

Registered Office  
Godrej One, 8<sup>th</sup> Floor, Pirojshanagar  
Eastern Express Highway, Vikhroli East  
Mumbai 400079, India.  
Phone +91 22 62109000  
Fax +91 22 62109999  
www.merck.co.in  
CIN: L99999MH1967PLC013726

**MERCK LIMITED**

Regd. Office: Godrej One, 8th Floor, Eastern Express Highway, Pirojshanagar, Vikhroli (East), Mumbai : 400 079.  
CIN No. L99999MH1967PLC013726, email : corpsec@merckgroup.com

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST MARCH, 2017**

(Rs in lakhs)				(Rs in lakhs)			
Particulars	3 months ended 31/03/2017	3 months ended 31/03/2016	Sr. No.	Particulars	3 months ended 31/03/2017	3 months ended 31/03/2016	
	Unaudited	Unaudited					
<b>1. Income from operations</b>			<b>1.</b>	<b>Segment Revenue</b>			
a) Net Sales/income from operations	22,987.69	21,028.55		a) Pharmaceuticals	18,814.53	16,921.35	
b) Other operating income	704.51	525.71		b) Chemicals	4,877.67	4,632.91	
<b>Total income from operations (net)</b>	<b>23,692.20</b>	<b>21,554.26</b>		<b>Total</b>	<b>23,692.20</b>	<b>21,554.26</b>	
<b>2. Expenses</b>				Less : Inter segment revenue	-	-	
a) Cost of materials consumed	5,598.20	6,396.80		Income from operations (net)	23,692.20	21,554.26	
b) Purchases of stock-in-trade	4,097.26	2,192.38	<b>2.</b>	<b>Segment Results (Profit before Tax and interest from each segment)</b>			
c) Changes in inventories of finished goods, work-in-progress and stock in trade	(479.15)	(67.19)		a) Pharmaceuticals	2,025.80	358.15	
d) Employee benefits expense	4,096.41	3,505.93		b) Chemicals	(236.90)	104.40	
e) Depreciation and amortisation expense	623.40	625.08		<b>Total</b>	<b>1,788.90</b>	<b>462.55</b>	
f) Other expenses	8,116.59	8,390.18		Less : Other un-allocable expenditure net off un-allocable income	(517.25)	(588.71)	
<b>Total expenses</b>	<b>22,052.71</b>	<b>21,043.18</b>		<b>Total Profit before Tax</b>	<b>2,306.15</b>	<b>1,051.26</b>	
<b>3. Profit from operations before other income, finance costs and exceptional items (1-2)</b>	<b>1,639.49</b>	<b>511.08</b>	<b>3.</b>	<b>Capital Employed</b>			
<b>4. Other Income</b>	<b>667.51</b>	<b>541.30</b>		<b>Segment Assets</b>			
<b>5. Profit from ordinary activities before finance costs and exceptional items (3+4)</b>	<b>2,307.00</b>	<b>1,052.38</b>		Pharmaceuticals	35,290.21	29,570.92	
<b>6. Finance Costs</b>	<b>0.85</b>	<b>1.12</b>		Chemicals	13,912.02	18,186.33	
<b>7. Profit from ordinary activities after finance costs but before exceptional items (5-6)</b>	<b>2,306.15</b>	<b>1,051.26</b>		Unallocated	41,811.71	31,180.40	
<b>8. Exceptional items</b>	<b>-</b>	<b>-</b>		<b>Total Assets</b>	<b>91,013.94</b>	<b>78,937.65</b>	
<b>9. Profit from ordinary activities before tax (7+8)</b>	<b>2,306.15</b>	<b>1,051.26</b>		<b>Segment Liabilities</b>			
<b>10. Tax expense</b>	<b>823.45</b>	<b>211.15</b>		Pharmaceuticals	16,835.48	14,086.94	
<b>11. Net Profit from ordinary activities after tax (9-10)</b>	<b>1,482.70</b>	<b>840.11</b>		Chemicals	4,502.70	2,514.20	
<b>12. Extraordinary items (net of tax expense)</b>	<b>-</b>	<b>-</b>		Unallocated	1,428.95	647.98	
<b>13. Net Profit for the period (11+12)</b>	<b>1,482.70</b>	<b>840.11</b>		<b>Total Liabilities</b>	<b>22,767.13</b>	<b>17,249.12</b>	
<b>14. Other comprehensive income (net of taxes)</b>	<b>(36.68)</b>	<b>(14.55)</b>		<b>Capital Employed</b>			
<b>15. Total comprehensive income (net of taxes) (13+14)</b>	<b>1,446.02</b>	<b>825.56</b>		Pharmaceuticals	18,454.73	15,483.98	
<b>14. Paid-up equity share capital (Face Value Rs 10/- each)</b>	<b>1,659.94</b>	<b>1,659.94</b>		Chemicals	9,409.32	15,672.13	
<b>15. Earnings per share [before extraordinary items (net of tax)] (of Rs 10/- each) (not annualised):</b>				Unallocated	40,382.76	30,532.42	
(a) Basic	8.93	5.06		<b>Total</b>	<b>68,246.81</b>	<b>61,688.53</b>	
(b) Diluted	8.93	5.06					
<b>16. Earnings per share [after extraordinary items (net of tax)] (of Rs 10/- each) (not annualised):</b>							
(a) Basic	8.93	5.06					
(b) Diluted	8.93	5.06					

**Notes:**

- The above results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at its meeting held on 03 May 2017. These results have been subjected to "Limited Review" by the statutory auditors of the company. The review report has been filed with stock exchange and is available on the company's website.
- The Company adopted Indian Accounting Standards ("Ind AS") from 01 January 2017 and accordingly these results have been prepared in accordance with recognition and measurement principles laid down in Ind AS 34, Interim Financial Reporting prescribed under section 133 of Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India. Financial results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS 34. The figures of the quarter ended 31 March 2016 have not been subject to limited review or audit. However, the management has exercised necessary due diligence to ensure that the financial results provide true and fair view of the Company's affairs.
- Reconciliation of Net Profit as previously reported on account of transition from the previous GAAP to Ind-AS for the quarter ended 31 March 2016

Sr No	Particulars	Rs. in lakhs	
		Unaudited	
	Net Profit for the period under previous GAAP	1,224.58	
a.	Additional provision for doubtful debts based on expected credit loss method under Ind AS 109	(83.84)	
b.	Revenue recognition - measurement of revenue	(525.24)	
c.	Charge of imputed interest on security deposit	(1.13)	
d.	Deferred tax on above adjustments	211.17	
	Net Profit for the period under Ind AS	825.56	

- Figures for the previous quarter/year have been re-grouped/re-arranged wherever necessary.

For and on behalf of MERCK LIMITED



*[Signature]*  
N. Krishnan  
Executive Director

Place : Mumbai  
Date : 03 May 2017  
Please visit us at our website www.merck.co.in



# B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,  
Apollo Mills Compound  
N. M. Joshi Marg, Mahalaxmi  
Mumbai - 400 011  
India

Telephone +91 (22) 4345 5300  
Fax +91 (22) 4345 5399

## Limited Review Report on Quarterly Financial Results of Merck Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Merck Limited

We have reviewed the accompanying statement of unaudited financial results ("the Statement") of Merck Limited ("the Company") for the quarter ended 31 March 2017 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Attention is drawn to the fact that the figures for the corresponding quarter ended 31 March 2016 including the reconciliation of net profit under Ind AS of the corresponding quarter with net profit for the quarter reported under previous GAAP, as reported in these financial results have been approved by the Company's Board of Directors but have not been subjected to review.


This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 3 May 2017. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of the Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 5 July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**  
Chartered Accountants

Firm's Registration No: 101248W/W-100022



**Vikas R Kasat**  
Partner

Membership No: 105317

Mumbai  
03 May 2017